Providing access to risk prediction tools via the HL7 XML-formatted risk web service

Cancer risk prediction tools provide valuable information to clinicians but remain computationally challenging. Many clinics find that CaGene or HughesRiskApps fit their needs for easy- and ready-to-use software to obtain cancer risks; however, these resources may not fit all clinics’ needs. The HughesRiskApps Group and BayesMendel Lab therefore developed a web service, called “Risk Service”, which may be integrated into any client software to quickly obtain standardized and up-to-date risk predictions for BayesMendel tools (BRCAPRO, MMRpro, PancPRO, and MelaPRO), the Tyrer-Cuzick IBIS Breast Cancer Risk Evaluation Tool, and the Colorectal Cancer Risk Assessment Tool. Software clients that can convert their local structured data into the HL7 XML-formatted family and clinical patient history (Pedigree model) may integrate with the Risk Service. The Risk Service uses Apache Tomcat and Apache Axis2 technologies to provide an all Java web service. The software client sends HL7 XML information containing anonymized family and clinical history to a Dana-Farber Cancer Institute (DFCI) server, where it is parsed, interpreted, and processed by multiple risk tools. The Risk Service then formats the results into an HL7 style message and returns the risk predictions to the originating software client. Upon consent, users may allow DFCI to maintain the data for future research. The Risk Service implementation is exemplified through HughesRiskApps. The Risk Service broadens the availability of valuable, up-to-date cancer risk tools and allows clinics and researchers to integrate risk prediction tools into their own software interface designed for their needs. Each software package can collect risk data using its own interface, and display the results using its own interface, while using a central, up-to-date risk calculator. This allows users to choose from multiple interfaces while always getting the latest risk calculations. Consenting users contribute their data for future research, thus building a rich multicenter resource.

[1]  Karl W Broman,et al.  BayesMendel: an R Environment for Mendelian Risk Prediction , 2004, Statistical applications in genetics and molecular biology.

[2]  J. Stockman,et al.  Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome , 2008 .

[3]  G. Parmigiani,et al.  Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction , 2008, Breast Cancer Research.

[4]  V Shane Pankratz,et al.  Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Hormuzd A Katki,et al.  Incorporating medical interventions into carrier probability estimation for genetic counseling , 2007, BMC medical genetics.

[6]  G. Parmigiani,et al.  Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO , 2008, Statistics in medicine.

[7]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[8]  G. Parmigiani,et al.  Tailoring BRCAPRO to Asian-Americans. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[10]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[11]  Giovanni Parmigiani,et al.  Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO , 2012, Breast Cancer Research and Treatment.

[12]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[13]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[14]  Giovanni Parmigiani,et al.  PancPRO: risk assessment for individuals with a family history of pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Giovanni Parmigiani,et al.  Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. , 2010, Cancer research.

[16]  Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.

[17]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Brian Drohan,et al.  Identification and Management of Women at High Risk for Hereditary Breast/Ovarian Cancer Syndrome , 2009, The breast journal.

[19]  M. Gail,et al.  Colorectal cancer risk prediction tool for white men and women without known susceptibility. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.